SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq: AFFX) today announced that its technology powers the Ipsogen MapQuant Dx™ Genomic Grade, the first genomic test designed to provide a more precise measurement of tumor grade than previous techniques. Ipsogen, a leading French molecular diagnostic company, today launched the test, which resulted from the Powered by Affymetrix™ agreement signed in August 2007.
